Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma

BACKGROUND: Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance. However, even among RAS wild-type (WT) pa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Autores principales: Lièvre, Astrid, Ouine, Bérèngere, Canet, Jim, Cartier, Aurélie, Amar, Yael, Cacheux, Wulfran, Mariani, Odette, Guimbaud, Rosine, Selves, Janick, Lecomte, Thierry, Guyetant, Serge, Bieche, Ivan, Berger, Frédérique, de Koning, Leanne
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2017
Materias:
Molecular Diagnostics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5729470/
https://ncbi.nlm.nih.gov/pubmed/29024937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.353
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares